Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

In ASTRAEA (NCT01860976), abatacept significantly increased American College of Rheumatology criteria 20% (ACR20) responses at Week 24 versus placebo in patients with psoriatic arthritis (PsA). This post hoc analysis explored relationships between prospectively identified baseline characteristics [p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., McInnes, Iain B., Strand, Vibeke, FitzGerald, Oliver, Ahmad, Harris A., Elbez, Yedid, Banerjee, Subhashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256096/
https://www.ncbi.nlm.nih.gov/pubmed/32356115
http://dx.doi.org/10.1007/s00296-020-04564-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256096/
https://www.ncbi.nlm.nih.gov/pubmed/32356115
http://dx.doi.org/10.1007/s00296-020-04564-x

Ejemplares similares